WASHINGTON (Reuters) - U.S. regulators will allow experimental use of Insmed’s drug Iplex for certain patients with Lou Gehrig’s disease, the Food and Drug Administration said on Tuesday.
The drug is approved for treating a growth hormone deficiency but is not currently marketed because of a court order related to patent infringement, an FDA notice said.
The agency said a number of doctors had requested permission to use the drug for patients with Lou Gehrig’s disease, also known as amyotrophic lateral sclerosis or ALS. Similar drugs have been tested for the fatal neurological disease but failed to show benefit. Some trials suggested patients may fare worse with one of the medicines than a placebo, the FDA said.
GET YOUR FREE HGH &
- Get your own FREE copy of the groundbreaking report, "Seven Age Reversing Secrets" – packed with valuable tips and tricks to help you fight the aging process and have the highest quality of life possible!